| John A. Brem, Dpm | |
|
1512 Commerce St, Wellsburg, WV 26070-1323 | |
| (304) 737-2964 | |
| (304) 737-4882 |
| Full Name | John A. Brem, Dpm |
|---|---|
| Type | Facility |
| Speciality | Podiatrist |
| Location | 1512 Commerce St, Wellsburg, West Virginia |
| Accepts Medicare Assignments | Does not participate in Medicare Program. The facility may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1083792337 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 213E00000X | Podiatrist | (West Virginia) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| John A. Brem, Dpm 401 Market St, Suite 11, Steubenville, OH 43952-2881 Ph: (740) 282-0861 | John A. Brem, Dpm 1512 Commerce St, Wellsburg, WV 26070-1323 Ph: (304) 737-2964 |
News Archive
The state of the British economy has made the cut backs in NHS funding a major issue in the coming election. However no matter what the posturing is right now, and no politician wants to be seen making cuts here, there may be no other viable alternatives. No matter who forms the government after 6th May, they will be under great strain to keep their earlier promises of no health fund cuts.
Teleflex Incorporated, a leading global provider of medical technology products, today announced that it has entered into a definitive agreement to sell its SSI Surgical Services Inc. business to a privately-owned multi-service line healthcare company for approximately $25 million. The transaction is subject to customary closing conditions and is expected to close before the end of the first quarter of 2010.
Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by modulating T cell activity, presented results from preclinical studies with TRX518, an early-stage agent Tolerx is developing as a treatment for cancer. TRX518 is a monoclonal antibody to glucocorticoid-induced tumor necrosis factor receptor (GITR) and is designed to enhance the immune system's ability to attack tumors by activating and rendering T effector cells resistant to T regulatory cell suppression.
Atopix Therapeutics Ltd ("Atopix"), a biopharmaceutical company developing innovative CRTH2 antagonists for allergic disease, announced the results of a Phase IIb asthma study with their lead compound OC459 at the American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting , San Diego, California, USA on March 1st.
Research may help physicians give patients undergoing total knee arthroplasty a realistic expectation of surgery outcome based on their overall physical and mental health, US researchers believe.
› Verified 9 days ago
Complete Foot And Ankle Care Llc Podiatrist Medicare: Medicare Enrolled Practice Location: 1512 Commerce St, Wellsburg, WV 26070 Phone: 304-737-2964 Fax: 304-737-4822 |